Li Qiong, Liu Yu-Jia, Dong Di, Bai Xu, Huang Qing-Bo, Guo Ai-Tao, Ye Hui-Yi, Tian Jie, Wang Hai-Yi
Department of Radiology, Tianjin Nankai Hospital (Tianjin Hospital of Integrated Traditional Chinese and Western Medicine), Tianjin, China.
Department of Radiology, First Medical Center, Chinese PLA General Hospital, Beijing, China.
J Magn Reson Imaging. 2020 Nov;52(5):1557-1566. doi: 10.1002/jmri.27182. Epub 2020 May 28.
Nuclear grade is of importance for treatment selection and prognosis in patients with clear cell renal cell carcinoma (ccRCC).
To develop and validate an MRI-based radiomic model for preoperative predicting WHO/ISUP nuclear grade in ccRCC.
Retrospective.
In all, 379 patients with histologically confirmed ccRCC. Training cohort (n = 252) and validation cohort (n = 127) were randomly assigned.
FIELD STRENGTH/SEQUENCE: Pretreatment 3.0T renal MRI. Imaging sequences were fat-suppressed T WI, contrast-enhanced T WI, and diffusion weighted imaging.
Three prediction models were developed using selected radiomic features, radiomic and clinicoradiologic characteristics, and a model containing only clinicoradiologic characteristics. Receiver operating characteristic (ROC) curves and area under the curve (AUC) were used to assess the predictive performance of these models in predicting high-grade ccRCC.
The least absolute shrinkage and selection operator (LASSO) and minimum redundancy maximum relevance (mRMR) method were used for the selection of radiomic features and clinicoradiologic characteristics, respectively. Multivariable logistic regression analysis was used to develop the radiomic signature of radiomic features and clinicoradiologic model of clinicoradiologic characteristics.
The radiomic signature showed good performance in discriminating high-grade (grades 3 and 4) from low-grade (grades 1 and 2) ccRCC, with sensitivity, specificity, and AUC of 77.3%, 80.0%, and 0.842, respectively, in the validation cohort. The radiomic model, combining radiomic signature and clinicoradiologic characteristics, displayed good predictive ability for high-grade with sensitivity, specificity, and accuracy of 63.6%, 93.3%, and 88.2%, respectively, in the validation cohort. The radiomic model showed a significantly better performance than the clinicoradiologic model (P < 0.05).
Multiparametric MRI-based radiomic model can predict WHO/ISUP grade in patients with ccRCC with satisfying performance, and thus could help the physician to improve treatment decisions.
3 TECHNICAL EFFICACY STAGE: 2.
核分级对于透明细胞肾细胞癌(ccRCC)患者的治疗选择和预后至关重要。
开发并验证一种基于MRI的放射组学模型,用于术前预测ccRCC的WHO/ISUP核分级。
回顾性研究。
总共379例经组织学确诊的ccRCC患者。随机分为训练队列(n = 252)和验证队列(n = 127)。
场强/序列:治疗前3.0T肾脏MRI。成像序列包括脂肪抑制TWI、对比增强TWI和扩散加权成像。
使用选定的放射组学特征、放射组学和临床放射学特征以及仅包含临床放射学特征的模型开发了三种预测模型。采用受试者操作特征(ROC)曲线和曲线下面积(AUC)评估这些模型预测高级别ccRCC的性能。
分别采用最小绝对收缩和选择算子(LASSO)及最小冗余最大相关(mRMR)方法选择放射组学特征和临床放射学特征。采用多变量逻辑回归分析建立放射组学特征的放射组学特征图谱和临床放射学特征的临床放射学模型。
放射组学特征图谱在区分高级别(3级和4级)与低级别(1级和2级)ccRCC方面表现良好,在验证队列中,敏感性、特异性和AUC分别为77.3%、80.0%和0.842。结合放射组学特征图谱和临床放射学特征的放射组学模型对高级别有良好的预测能力,在验证队列中,敏感性、特异性和准确性分别为63.6%、93.3%和88.2%。放射组学模型的表现明显优于临床放射学模型(P < 0.05)。
基于多参数MRI的放射组学模型能够以令人满意的性能预测ccRCC患者的WHO/ISUP分级,从而有助于医生改进治疗决策。
3 技术疗效阶段:2。